March 2011. Volume 7. Number 1

Efficacy of antiemetic medication for prevention of nausea and vomiting in children treated with cancer chemotherapy

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD007786.
Reviewers: Perdikidis Olivieri L1, Bonillo Perales A2.
1EAP Juncal. Torrejón de Ardoz. Madrid. España.
2Hospital Torrecárdenas. Almería. España.
Correspondence: Leo Perdikidis Olivieri. Email: lperdikidis@gmail.com
Reception date: 08/11/2010
Acceptance date: 02/12/2010
Publication date: 09/12/2010

Abstract

Authors' conclusions: antiemetic medication and especially antagonists of 5-HT3 receptors are useful in preventing and treating nausea and vomiting associated with oncologic treatments. There is a lack of studies on the effect of treatment on anticipatory vomiting and nausea, but it is probable that they are not effective. Children with cancer and their families identify secondary effects caused by cancer treatment as the most disagreeable aspect of it.

Reviewers' commentary: this is a well designed and developed study that meets adequately the criteria for a systematic review. It reviews the studies on impact of vomiting and nausea in children with cancer, and the secondary effects of antiemetic medication (which are frequent and significant) and exposes the need for future research, especially on the impact on quality of life of these children.

How to cite this article

Perdikidis Olivieri L, Bonillo Perales A. Eficacia de los antieméticos para prevenir las náuseas y los vómitos en niños con tratamiento quimioterápico. Evid Pediatr. 2011;7:5.

AVC | Critically appraised articles

Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD007786.
Reviewers: Perdikidis Olivieri L1, Bonillo Perales A2.
1EAP Juncal. Torrejón de Ardoz. Madrid. España.
2Hospital Torrecárdenas. Almería. España.
Correspondence: Leo Perdikidis Olivieri. Email: lperdikidis@gmail.com
Reception date: 08/11/2010
Acceptance date: 02/12/2010
Publication date: 09/12/2010

How to cite this article

Perdikidis Olivieri L, Bonillo Perales A. Eficacia de los antieméticos para prevenir las náuseas y los vómitos en niños con tratamiento quimioterápico. Evid Pediatr. 2011;7:5.

References

  1. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology. 2007,7:10.
  2. González de Dios J, Balaguer Santamaría A. Revisión sistemática y metaanálisis (I): conceptos básicos. Evid Pediatr. 2007;3:107.
  3. Systemic Treatment Disease Site Group. Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 [en línea] [fecha de consulta: 13-X-2010]. Disponible en: http://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc12_3f.pdf
  4. Cancer Care Ontario. Ontario Ministry of Health and Long Term Care. Cancer Care Ontario Practice Guidelines Initiative. Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Actualización año 2003. Practice Guideline Report. 2000;12-3.
  5. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18:233-40.
  6. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-8.
09/12/2010

Linked Comment